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abstract
Objective To evaluate the effectiveness of self management 
as a first line intervention for men with lower urinary tract 
symptoms.
Design Randomised controlled trial.
Setting A teaching hospital and a district general hospital 
in London.
Participants 140 men (mean age 63 (SD 10.7) years), 
recruited between January 2003 and April 2004, referred by 
general practitioners to urological outpatient departments 
with uncomplicated lower urinary tract symptoms.
Interventions Self management and standard care (n=73) 
or standard care alone (n=67). The self management 
group took part in three small group sessions comprising 
education, lifestyle advice, and training in problem solving 
and goal setting skills.
Main outcome measures The primary outcome measure 
was treatment failure measured at 3, 6, and 12 months. 
Symptom severity (international prostate symptom score; 
higher scores represent a poorer outcome) was used as a 
secondary outcome.
Results At three months, treatment failure had occurred in 
7 (10%) of the self management group and in 27 (42%) of 
the standard care group (difference=32%, 95% confidence 
interval 18% to 46%). Corresponding differences in the 
frequency of treatment failure were 42% (27% to 57%) 
at six months and 48% (32% to 64%) at 12 months. At 
three months, the mean international prostate symptom 
score was 10.7 in the self management group and 16.4 
in the standard care group (difference=5.7, 3.7 to 7.7). 
Corresponding differences in score were 6.5 (4.3 to 8.7) at 
six months and 5.1 (2.7 to 7.6) at 12 months.
Conclusions Self management significantly reduced 
the frequency of treatment failure and reduced urinary 
symptoms. Because of the large observed benefit of self 
management, the results of this study support the case for a 
large multicentre trial to confirm whether self management 
could be considered as first line treatment for men with 
lower urinary tract symptoms.
Trial registration National Research Register N0263115137; 
Clinical trials NCT00270309.
IntroductIon
Standard care for men with lower urinary tract symp-
toms has developed into a “cascade” that escalates 
from “watchful waiting” through a variety of drugs to 
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surgery.1 2 �ealthcare professionals involved in the care      
of men with lower urinary tract symptoms routinely 
advise lifestyle modifications. �owever, the type of 
advice given varies considerably.3 A formal consen-
sus development exercise was carried out to define the 
lifestyle modifications that are likely to be effective in 
improving lower urinary tract symptoms.4
We developed a self management intervention for 
men with lower urinary tract symptoms that incorpo-
rated the recommendations of the consensus panel.4 
The purpose of the programme was to reduce urinary 
symptoms and to delay or avoid an escalation in treat-
ment. We did a randomised controlled trial in two cen-
tres to compare men with lower urinary tract symptoms 
who participated in a self management programme in 
addition to standard care with those who received 
standard care alone.
Methods
Patient population—We recruited men with uncompli-
cated lower urinary tract symptoms from the outpatient 
departments of two urological centres in London. We 
randomised the men either to attend a self manage-
ment programme in addition to standard care or to 
standard care alone. All patients aged over 40 with 
lower urinary tract symptoms who were referred for the 
first time by their general practitioner were eligible for 
inclusion. We excluded some men on the basis of drug 
treatment, recent surgery, complications potentially 
related to their symptoms, or severe comorbidity. 
Standard care—Standard care in the two participat-
ing centres began with watchful waiting. Escalation to 
medical treatment and surgery was left to the discretion 
of the clinician and patient. 
Intervention—In addition to standard care, the inter-
vention group took part in small group sessions (five 
to eight men), each lasting between 1.5 and 2 hours, 
which were scheduled one, two, and six weeks after 
randomisation. The aim of these sessions was to bring 
about modification of lifestyle (fluid management, 
avoidance of caffeine, and use of alcohol) and specific 
changes in behaviour (bladder retraining, double void-
ing, and urethral milking). (See appendix on bmj.com 
and reference 5 for a description of the information 
component.) We designed the sessions to enable the 
participants to learn techniques of problem solving 
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and goal setting. At 3, 6, and 12 months, clinicians 
who were not involved in the conduct of the trial saw 
participants in the urology outpatient departments. 
Outcomes—The primary outcome was treatment failure 
(rise of 3 points or more on the international prostate 
symptom score, use of drugs to control lower urinary 
tract symptoms, acute urinary retention, or surgical 
intervention) during follow-up.5 6 Secondary outcomes 
included severity of symptoms (international prostate 
symptom score), troublesomeness of symptoms (benign 
prostatic hypertrophy impact index), and disease spe-
cific quality of life (American Urological Association 
quality of life score).5 7 
Statistical analysis—We analysed outcomes at 3, 6, and 
12 months separately on an intention to treat basis. We 
did regression to adjust comparisons for potential imbal-
ances in the baseline characteristics of the two groups 
(age, severity of symptoms, duration of symptoms, level 
of education, and number of comorbidities).
results
Of the 186 patients who were eligible for randomisa-
tion during the recruitment period, 46 were excluded. 
Of the 140 men who were included, we randomised 
73 to participate in the self management programme 
and 67 to standard care alone. Compliance with the self 
management programme was high; 68 (93%) patients 
attended all three sessions. The five patients who did 
not attend were included in the self management group 
for analysis.
B�seline ch�r�cteristics
The distributions of the patient demographics in the 
self management group and the standard care group 
were broadly similar (see bmj.com). Comorbidity was 
slightly more frequent in the self management group. 
Although most patients in the two groups fell in the 
moderate category of symptom severity, more patients 
in the standard care group had either mild or severe 
symptoms.
Prim�ry outcome
At 3, 6, and 12 months, treatment failure was consider-
ably more frequent in patients who were randomised 
to standard care alone than in those randomised to self 
management (table 1). The principal reasons for failure 
were prescription of α blockers or a rise in international 
prostate symptom score (table 2). Adjustment for base-
line characteristics did not change these results.
The results in table 1 represent only patients with 
complete information at 3, 6, and 12 months. When we 
imputed missing values by using results of the previous 
measurements, only small changes occurred in the dif-
ferences between the two groups and these differences 
remained statistically significant.
Second�ry outcomes
At 3, 6, and 12 months, patients who were ran-
domised to self management had less severe symp-
toms than patients randomised to standard care alone 
(table 1). The differences in international prostate 
symptom score increased slightly when we adjusted 
them for baseline characteristics. Patients who were 
randomised to self management were also less trou-
bled by their symptoms and had a better quality of 
life than patients who were randomised to standard 
care alone (table 1). When we imputed missing values 
by using results of the previous measurements, the 
differences in symptom severity, troublesomeness, 
and quality of life remained statistically significant at 
3, 6, and 12 months.
dIscussIon
Self management in addition to standard care sig-
nificantly reduced the rate of treatment failure and 
improved urinary symptoms, compared with standard 
care alone. The difference in symptoms between the 
treatment groups is twice as large as that seen when 
medical treatment is compared with placebo.1 The 
benefits of self management were seen early and were 
sustained at six and 12 months.
Methodologic�l consider�tions
The treatment of men in the standard care group may 
have been contaminated because of the conduct of the 
trial. This contamination, which would have reduced 
the difference between the groups, may have occurred 
through changes in the advice the clinicians gave to 
their patients or through direct communication between 
patients allocated to different groups. �owever, the 
crucial difference between the two treatment groups is 
the problem solving and goal setting skills that patients 
acquired as a result of attending the programme. These 
skills are unlikely to have been conferred during the 
clinical consultation or transferred from one patient to 
another. 
Lack of blinding of patients to the treatment allo-
cation is another source of bias. �owever, we asked 
patients not to reveal their allocation to the clinicians 
table 1 | Primary and secondary outcomes at 3, 6, and 12 months. Values are mean (SD) unless 
stated otherwise 
Self management (n=73) Standard care (n=67)
Value No missing Value No 
missing
Difference 
(95% CI)
P value
Three month outcomes
Treatment failures (% (No)) 10 (7) 2 42 (27) 2 32 (18 to 46) <0.001
IPSS 10.7 (5.9) 2 16.4 (5.8) 3 5.7 (3.7 to 7.7) <0.001
BPH impact index 3.3 (2.8) 2 4.7 (2.6) 3 1.4 (0.5 to 2.3) 0.003
AUA-QoL score 2.8 (1.2) 2 3.4 (1.1) 3 0.7 (0.3 to 1.1) <0.001
Six month outcomes
Treatment failures (% (No)) 19 (13) 4 61 (39) 3 42 (27 to 57) <0.001
IPSS 10.4 (6.1) 6 16.9 (6.4) 6 6.5 (4.3 to 8.7) <0.001
BPH impact index 3.5 (2.9) 7 4.8 (2.8) 6 1.4 (0.4 to 2.4) 0.008
AUA-QoL score 2.6 (1.3) 6 3.3 (1.4) 6 0.6 (0.2 to 1.1) 0.008
Twelve month outcomes
Treatment failures (% (No)) 31 (18) 14 79 (44) 11 48 (32 to 64) <0.001
IPSS 10.2 (6.1) 20 15.4 (6.6) 16 5.1 (2.7 to 7.6) <0.001
BPH impact index 3.0 (3.3) 18 4.3 (2.9) 16 1.2 (0 to 2.4) 0.04
AUA-QoL score 2.6 (1.3) 19 3.1 (1.2) 15 0.5 (0 to 1.0) 0.03
AUA-QoL=American Urological Association quality of life; BPH=benign prostatic hypertrophy; IPSS=international 
prostate symptom score.
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doing the consultations after randomisation. The effect 
of this lack of blinding would be small because the self 
management programme was carried out only dur-
ing the first six weeks and the first clinical visit took 
place at least six weeks after the last session of the 
programme. By that time, the severity of symptoms 
expressed by patients will have determined treat-
ment decisions rather than the clinician’s awareness of 
whether a patient had participated in the self manage-
ment programme.
table 2 | Reasons for treatment failure at 3, 6, and 12 months. 
Values are numbers of patients
Self 
management
Standard care
Treatment failures at three months 7 27
Reasons for treatment failures at three 
months:
 α blocker 3 12
 Finasteride 0 0
 Anticholinergic 1 1
 Surgery 1 1
 Catheterised for acute urinary
 retention
0 2
 Other drug treatment 0 0
 Rise in IPSS of ≥3 points 4 20
Treatment failures at six months 13 39
Reasons for failures between three and 
six months:
 α blocker 0 4
 Finasteride 0 1
 Anticholinergic 3 0
 Surgery 0 0
 Catheterised for acute urinary 
 retention
0 0
 Other drug treatment 0 1
 Rise in IPSS of ≥3 points 3 6
Treatment failures at 12 months 18 44
Reasons for failures between six and 
12 months:
 α blocker 3 2*
 Finasteride 1 0
 Anticholinergic 0 0
 Surgery 0 0
 Catheterised for acute urinary 
 retention
0 0
 Other drug treatment 0 0
 Rise in IPSS of ≥3 points 1 4*
IPSS=international prostate symptom score. 
*One patient was prescribed an α blocker and had a rise in IPSS of ≥3 points.
What Is already knoWn on thIs topIc
Standard treatment for men with lower urinary tract symptoms has developed into a 
“cascade” that starts with watchful waiting and moves up to drugs and surgery
Self management interventions that aim to enhance patients’ problem solving and goal 
setting skills have been shown to be an effective treatment for arthritis, diabetes, and 
asthma.
What thIs study adds
Self management was at least as effective as medical treatment for men with uncomplicated 
lower urinary tract symptoms
expl�n�tions for obser�ed results
Our study indicates that self management may be a 
very effective treatment for men with lower urinary 
tract symptoms. A possible explanation is that the 
influences of lifestyle modification for lower urinary 
tract symptoms are immediately apparent to patients, 
in contrast to the delayed effects associated with life-
style modifications for other chronic diseases. This 
immediacy of effect provides positive feedback. Fur-
thermore, patients can try out the effects of the differ-
ent lifestyle modifications and adapt them according 
to their individual circumstances. 
Severity of symptoms in the standard care group 
remained more or less the same compared with base-
line. This apparent lack of effect of standard care in 
our study contributes to the large difference in symp-
tom severity between the two treatment groups. We 
would have expected an improvement in symptoms 
with standard care either through “regression to the 
mean” or as a result of some of the men being offered 
medical or surgical treatment. �owever, the impact of 
regression to the mean is likely to be small. Symptom 
severity was not one of the inclusion criteria, and the 
time interval between referral and recruitment was 
long (four to six months) and variable, which will have 
diminished the link between severity of symptoms at 
the time of referral and at the time of recruitment. Fur-
thermore, only about 20% of the men who received 
standard care alone were given medical or surgical 
treatment, and the rest remained untreated.
A multicentre pragmatic randomised controlled 
trial should now be carried out to determine whether 
our results can be replicated in everyday clinical prac-
tice.8
Conclusion
The results from this small two centre study are 
sufficiently impressive that a policy of self manage-
ment as described in this paper has the potential to 
become the ideal first line treatment for men with 
uncomplicated lower urinary tract symptoms, pro-
vided that further studies show their generalisability. 
The only imaginable harm that can result from self 
management is that for some patients medical or 
surgical treatment is postponed.
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abstract
Objective To determine whether providing mothers of 
babies in neonatal intensive care units with audiotapes of 
their conversations with a neonatologist improves recall of 
information and psychological wellbeing.
Design Randomised, single blinded trial.
Setting Neonatal intensive care unit, north Queensland, 
Australia.
Participants 200 mothers of babies in a neonatal intensive 
care unit.
Interventions Mothers given (n=102) or not given (n=98) 
audiotapes of their conversations with a neonatologist.
Main outcome measures Recall of information, attitudes 
to and use of the tape, satisfaction with conversations, 
postnatal depression, anxiety, general health, and stress 
about parenting, at 10 days and four and 12 months. 
Results 91% (n=93) of mothers in the tape group listened 
to the tape (once by day 10, twice by four months, and 
three times by 12 months; range 1-10). At 10 days and four 
months, mothers in the tape group recalled significantly 
more information about diagnosis, treatment, and outcome 
than mothers in the control group. At four months mothers 
in the tape group were 75% more likely to recall all of the 
information about treatment than mothers in the control 
group (59% v 34%; risk ratio 1.75, 95% confidence interval 
1.27 to 2.4). Six mothers, all in the control group, could 
not recall their conversations. No statistically significant 
differences were found between the groups in satisfaction 
with conversations (10 days), postnatal depression and 
anxiety scores (10 days, four and 12 months), and stress 
about parenting (12 months).
Conclusion Providing the mothers of babies in neonatal 
intensive care units with audiotapes of conversations with a 
neonatologist enhanced their recall of information (up to four 
months). The taped conversations did not affect the mothers’ 
wellbeing or satisfaction with the neonatologist. 
Trial registration Australian Clinical Trials Registry 
12606000478516.
IntroductIon
Several studies have found that giving adults with can-
cer an audiotape of their initial conversations with 
oncologists improved their psychological distress, 
anxiety, satisfaction with conversations, and recall 
of information whereas other authors found no ben-
efits.1-7 We carried out a randomised single blind trial 
to compare the effects of providing or not providing 
mothers of babies in neonatal intensive care units with 
an audiotape of their conversations with the neona-
tologist. 
Methods
Mothers were eligible for the study if their babies 
were admitted to the neonatal intensive care unit at 
the Townsville �ospital, the regional neonatal unit 
for north Queensland (see bmj.com). The study was 
a randomised controlled trial of audiotape provision, 
with the neonatal team blinded to allocation. Before 
the first conversation the mothers completed a ques-
tionnaire eliciting personal details, anxiety scores, and 
preferences for information and involvement in deci-
sion making. A randomisation service then allocated 
the mother to receive or not to receive a tape of their 
conversations with a neonatologist. 
After randomisation the initial conversation and 
subsequent conversations of significance were taped 
and analysed. The mothers in the experimental arm 
received a tape of each of the conversations and a 
tape recorder.
Ten days and four months after the initial conversa-
tion the researcher interviewed the mothers to docu-
ment their recall of the diagnosis, tests, treatment, and 
outcome of their babies as conveyed by the neona-
tologist. Mothers also completed a questionnaire to 
ascertain views of the taping, use of the tapes, anxiety, 
general health, depression, marital satisfaction, social 
support, and satisfaction with conversations held with 
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